Enhanced cellular therapy: revolutionizing adoptive cellular therapy

• Published in: Experimental hematology & oncology Vol. 13; no. 1; pp. 47 - 23
• Main Authors: Xu, Meng-Yao, Zeng, Na, Liu, Chen-Qian, Sun, Jian-Xuan, An, Ye, Zhang, Si-Han, Xu, Jin-Zhou, Zhong, Xing-Yu, Ma, Si-Yang, He, Hao-Dong, Hu, Jia, Xia, Qi-Dong, Wang, Shao-Gang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.04.2024; BMC
• Subjects: Adoptive cellular therapy; Antimitotic agents; Antineoplastic agents; Biological products; Enhanced cellular therapy; Genetic engineering; Genetically modified organisms; Immune checkpoint inhibitor; Immunity; Immunotherapy; Medical colleges; Oncolytic virus; PROTAC; Proteolysis; Tumors; Oncolytic virus; Immune checkpoint inhibitor; Enhanced cellular therapy; PROTAC; Immunotherapy; Adoptive cellular therapy
• ISSN: 2162-3619; 2162-3619
• DOI: 10.1186/s40164-024-00506-6

Enhanced cellular therapy has emerged as a novel concept following the basis of cellular therapy. This treatment modality applied drugs or biotechnology to directly enhance or genetically modify cells to enhance the efficacy of adoptive cellular therapy (ACT). Drugs or biotechnology that enhance the killing ability of immune cells include immune checkpoint inhibitors (ICIs) / antibody drugs, small molecule inhibitors, immunomodulatory factors, proteolysis targeting chimera (PROTAC), oncolytic virus (OV), etc. Firstly, overcoming the inhibitory tumor microenvironment (TME) can enhance the efficacy of ACT, which can be achieved by blocking the immune checkpoint. Secondly, cytokines or cytokine receptors can be expressed by genetic engineering or added directly to adoptive cells to enhance the migration and infiltration of adoptive cells to tumor cells. Moreover, multi-antigen chimeric antigen receptors (CARs) can be designed to enhance the specific recognition of tumor cell-related antigens, and OVs can also stimulate antigen release. In addition to inserting suicide genes into adoptive cells, PROTAC technology can be used as a safety switch or degradation agent of immunosuppressive factors to enhance the safety and efficacy of adoptive cells. This article comprehensively summarizes the mechanism, current situation, and clinical application of enhanced cellular therapy, describing potential improvements to adoptive cellular therapy.